HAVCR2 and neoplasm: Moreover, in a mouse model, coadministration of TMAO with ICIs (anti-PD-1 and/or anti-TIM-3) can obviously reduce tumor burden and improve survival patients compared with TMAO or ICIs alone (Mirji et al., 2022).